Circadian Technologies Limited Share Price Australian S.E.
Equities
AU000000CIR6
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- AUD | - |
28/05 | Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD | CI |
28/05 | Opthea Completes Enrollments in COAST, ShORe Trials | MT |
Sales 2024 * | 922K 613K 51.15M | Sales 2025 * | 17.45M 11.61M 968M | Capitalization | 338M 225M 18.76B |
---|---|---|---|---|---|
Net income 2024 * | -278M -185M -15.43B | Net income 2025 * | -224M -149M -12.43B | EV / Sales 2024 * | 533 x |
Net Debt 2024 * | 154M 102M 8.53B | Net Debt 2025 * | 212M 141M 11.75B | EV / Sales 2025 * | 31.5 x |
P/E ratio 2024 * |
-1.11
x | P/E ratio 2025 * |
-1.58
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.31% |
Managers | Title | Age | Since |
---|---|---|---|
Frédéric Guerard
CEO | Chief Executive Officer | 51 | 27/23/27 |
Megan Baldwin
FOU | Founder | 49 | 01/08/01 |
Peter F. Lang
DFI | Director of Finance/CFO | 52 | 27/23/27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeremy Levin
CHM | Chairman | 70 | 05/20/05 |
Quinton Oswald
BRD | Director/Board Member | - | 21/22/21 |
Lawrence Gozlan
BRD | Director/Board Member | 45 | 24/20/24 |
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |